Fulgent Genetics
FLGT
254 hedge funds and large institutions have $985M invested in Fulgent Genetics in 2021 Q2 according to their latest regulatory filings, with 59 funds opening new positions, 95 increasing their positions, 55 reducing their positions, and 60 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
73% more repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 55
1.91% more ownership
Funds ownership: 34.87% → 36.77% (+1.9%)
1% more capital invested
Capital invested by funds: $973M → $985M (+$12.6M)
1% less funds holding
Funds holding: 256 → 254 (-2)
2% less first-time investments, than exits
New positions opened: 59 | Existing positions closed: 60
8% less call options, than puts
Call options by funds: $104M | Put options by funds: $112M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$37.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$18.2M |
| 3 |
JP Morgan Chase
New York
|
+$13.1M |
| 4 |
State Street
Boston,
Massachusetts
|
+$12M |
| 5 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$6.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$21.1M |
| 2 |
Morgan Stanley
New York
|
-$15.6M |
| 3 |
RIM
Ranger Investment Management
Dallas,
Texas
|
-$12.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$11.6M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$10.1M |
FLGT Hedge Fund Activity: Q2 2021 in Review
254 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Fulgent Genetics (FLGT) for Q2 2021, worth a combined $985M — up 1.3% from $973M a quarter earlier.
Sellers outnumbered buyers: 60 funds closed out of FLGT and 59 opened new positions — a net loss of 1 holder — while 55 trimmed existing stakes and 95 added.
The largest buyer was BlackRock, adding an estimated $37.6M. The largest seller was Invesco, cutting an estimated $21.1M.
- 254 institutional investors held Fulgent Genetics (FLGT) as of Q2 2021, down from 256 in Q1 2021.
- Funds reported $985M of Fulgent Genetics stock for Q2 2021, up 1.3% quarter-over-quarter.
- 59 funds opened new Fulgent Genetics positions in Q2 2021 and 60 closed out, a net change of -1 holder.
- The largest Fulgent Genetics buyer in Q2 2021 was BlackRock, an estimated $37.6M added.
- The largest Fulgent Genetics seller in Q2 2021 was Invesco, an estimated $21.1M sold.
Based on aggregated 13F filings for Q2 2021.